SUBSCRIBE
SUBSCRIBE
News   Business

Biovail Corporation And Athpharma Limited To End Pact On Heart Drugs

July 24, 2006 | 
1 min read
TORONTO, July 24 (Reuters) - Biovail Corp. (BVF.TO: Quote, Profile, Research) (BVF.N: Quote, Profile, Research) and Athpharma Ltd. said on Monday they will terminate a joint development deal related to four development-stage cardiovascular products.
Alliances
MORE ON THIS TOPIC
Contemporary art collage. Purple hand holding fan of dollar bills against bright yellow background. stock photo
Venture capital
Ambros Launches With $125M To Bring Italian Non-Opioid Pain Drug to America
December 16, 2025
 · 
1 min read
 · 
Annalee Armstrong
Illustration of businessman running back around
Autoimmune disease
Sanofi Taps Dren Again in up to $1.7B Autoimmune Partnership
December 15, 2025
 · 
1 min read
 · 
Annalee Armstrong
Rheumatoid arthritis (RA) commonly causes inflammation in the hands, leading to pain, swelling, and stiffness in the joints, particularly the small joints of the fingers and wrists. This inflammation results from the immune system attacking the body's own joint tissues, causing the synovium (lining of the joint) to become inflamed and release chemicals that damage nearby tissues.
Mergers & acquisitions
Sobi Makes $1.5B Gout Play With Arthrosi Acquisition
December 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Pfizer, Geron Downsize To Streamline Costs
December 12, 2025
 · 
95 min read
 · 
BioSpace Editorial Staff